



APERTUS PHARMACEUTICALS

Collaborate

Create

Deliver

NEWS RELEASE

November 19, 2014

FOR IMMEDIATE RELEASE

www.apertuspharma.com

Contact: Rick Ryan

Phone: 866-576-2746

Email: rick.ryan@apertuspharma.com

**St. Louis-based Apertus Pharmaceuticals,
Pulse Therapeutics partner to improve stroke recovery**

Apertus Pharmaceuticals is proud to be collaborating on the development of a new medical device designed to potentially improve the treatment of stroke victims. Through the use of Magnetically Enhanced Diffusion, or MED, iron core MicroBeads, are guided to blockages in brain arteries and designed to augment the delivery of powerful FDA approved clot-busting drugs in the hopes that flow can be restored to brain tissue.

“Apertus is excited to collaborate with Pulse Therapeutics,” said Rick Ryan, chief executive officer of Apertus Pharmaceuticals. “This partnership has great potential to add to the regional economy through job creation while further bolstering St. Louis’ standing as a major science hub in the U.S.”

Pulse developed the concept for the novel device, while Apertus is producing the product that will soon be tested in future clinical trials.

“Pulse is extremely pleased to be working with the talented scientific team at Apertus”, said Sean Morris, Pulse CEO. “Their capabilities complement the Pulse team and together we have a solid scientific staff to further develop this technology.”

-END-

In addition to supporting medical device development **Apertus Pharmaceuticals** provides preclinical synthesis/process development and manufacture of Active Pharmaceutical Ingredients (APIs), drug discovery research and development services, such as hit/lead chemical synthesis and process improvement, as well as analytical chemistry services to the pharmaceutical and related markets. Visit apertuspharma.com for more information.

Pulse Therapeutics has developed a new approach, termed Magnetically-Enhanced Diffusion (MED), to improve the fluid dynamics in poor to zero flow vascular anatomical locations. By using a rotating external magnetic field (MED system) to preferentially direct the company’s intravenously injected, iron-oxide core MED MicroBeads, a new fluidic current can be created within stagnant regions to better convey physician-selected agents. The system is composed of two components: the MED workstation and the MED MicroBeads.